Compare GALT & DSAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GALT | DSAC |
|---|---|---|
| Founded | 2000 | 2025 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.3M | 343.9M |
| IPO Year | 2008 | 2025 |
| Metric | GALT | DSAC |
|---|---|---|
| Price | $2.90 | $10.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 185.4K | ★ 188.4K |
| Earning Date | 11-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $9.90 |
| 52 Week High | $7.13 | $10.47 |
| Indicator | GALT | DSAC |
|---|---|---|
| Relative Strength Index (RSI) | 35.26 | 36.15 |
| Support Level | $2.78 | $9.90 |
| Resistance Level | $3.30 | $10.18 |
| Average True Range (ATR) | 0.30 | 0.01 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 5.13 | 4.00 |
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Daedalus Special Acquisition Corp is a blank check company.